Anna Raciborska: Clinical Trials

3 active not recruiting, 2 recruiting. 4 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	4	Active not recruiting 2, Recruiting 2
Phase 3	1	Active not recruiting 1

Follow Anna Raciborska: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma Mifamurtide, Sorafenib - Osteosarcoma	Phase 2	Recruiting	Anna Raciborska	40	2026-04-01	2026-10-07
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Naxitamab - Ewing Sarcoma	Phase 2	Recruiting	Anna Raciborska	24	2023-10-24	2026-10-07
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging fluorodeoxyglucose (18F-FDG) - Histiocytosis	Phase 3	Active not recruiting	Anna Raciborska	150	2021-04-01	2026-10-07
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis Vemurafenib - Histiocytosis	Phase 2	Active not recruiting	Anna Raciborska	25	2021-04-01	2026-10-07
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients Trametinib - Histiocytosis	Phase 2	Active not recruiting	Anna Raciborska	12	2021-04-01	2026-10-07

Conditions studied

Histiocytosis (3)  ·  Histiocytosis, Langerhans-Cell (3)  ·  Osteosarcoma (1)  ·  Sarcoma, Ewing (1)

Interventions

Fluorodeoxyglucose F18 (1)  ·  Sorafenib (1)  ·  Vemurafenib (1)  ·  mifamurtide (1)  ·  naxitamab (1)  ·  trametinib (1)

Countries

Poland (5)

Results publications

PMID 32733795, PMID 33572900, PMID 33844437, PMID 34885651, PMID 35327550, PMID 35681553, PMID 35880942